DGA S.A. Logo

DGA S.A.

Consulting, training, and EU-funded project services for public and private organizations.

DGA | WAR

Overview

Corporate Details

ISIN(s):
PLDGA0000019 (+1 more)
LEI:
259400DTDT4GWZLEL890
Country:
Poland
Address:
Poznań Towarowa 37, 61-896 Poznań
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

DGA S.A. is a consulting and advisory group with over 35 years of experience in providing innovative solutions and professional guidance. The company's core activities include business and management consulting, corporate restructuring advisory, and the implementation of comprehensive training programs for both individuals and organizations. DGA specializes in acquiring and executing projects co-financed by external sources, including European Union funds. The firm actively fosters innovation through incubation and acceleration programs for startups and social initiatives. Its diverse service portfolio also covers labor market activation, educational development programs, and specialized coaching. DGA serves a broad clientele, ranging from micro to large enterprises, public institutions, and non-governmental organizations.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-30 17:17
Interim Report
Oświadczenie Zarządu
Polish 1.0 MB
2025-09-30 17:17
Audit Report / Information
Raport z przeglądu sprawozdania finansowego DGA S.A.
Polish 411.5 KB
2025-09-30 17:17
Management Discussion and Analysis
Sprawozdanie Zarządu z działalności DGA S.A. za I półrocze 2025 r
Polish 1.5 MB
2025-09-30 17:17
Annual / Quarterly Financial Statement
Sprawozdanie finansowe DGA S.A. za I półrocze 2025 r.
Polish 1.8 MB
2025-07-31 14:15
Regulatory News Service
Zawiadomienie o zejściu poniżej progu 5% ogólnej liczby głosów w Spółce - Conte…
Polish 1.8 KB
2025-07-30 15:04
Major Shareholding Notification
Zawiadomienie akcjonariusza
Polish 78.4 KB
2025-07-30 15:04
Major Shareholding Notification
Zawiadomienie o przekroczeniu progu 5% ogólnej liczby głosów w Spółce - Content…
Polish 1.2 KB
2025-07-29 13:56
Regulatory News Service
Otrzymanie podpisanego egzemplarza umowy znaczącej - Content (PL)
Polish 475 bytes
2025-07-17 15:22
Regulatory News Service
Podpisanie znaczącej umowy - Content (PL)
Polish 1.3 KB
2025-05-29 17:26
Management Discussion and Analysis
Informacje uzupełniające i komentarz Zarządu
Polish 1.5 MB
2025-05-29 17:26
Quarterly Report
Jednostkowe sprawozdanie finansowe DGA S.A. za I kw. 2025 r.
Polish 1.7 MB
2025-05-22 16:05
Declaration of Voting Results & Voting Rights Announcements
Lista akcjonariuszy posiadających co najmniej 5% liczby głosów na Zwyczajnym Wa…
Polish 1.0 KB
2025-05-22 15:56
Post-Annual General Meeting Information
Treść podjętych uchwał
Polish 204.0 KB
2025-05-22 15:56
Post-Annual General Meeting Information
Treść uchwał podjętych przez Zwyczajne Walne Zgromadzenie w dniu 22 maja 2025 r…
Polish 751 bytes
2025-04-24 15:10
Environmental & Social Information
Podpisanie umowy na realizację projektu. pt. "Zielona gospodarka - szkolenia i …
Polish 1.0 KB

Automate Your Workflow. Get a real-time feed of all DGA S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for DGA S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway NYKD
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland OCS
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea 244460
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea 382150
Onconic Therapeutics Inc. Logo
Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.
South Korea 476060
OncoTherapy Science, Inc. Logo
Develops targeted cancer therapies and provides TCR repertoire analysis services.
Japan 4564
Onxeo Logo
Developing precision-guided therapeutics using small antibodies for complex diseases.
France ALONX
Openedges Technology, Inc. Logo
Semiconductor IP provider of memory subsystem & AI platform IP for AI, HPC, and IoT SoCs.
South Korea 394280
Openjobmetis Logo
Employment agency providing staffing, recruitment, and HR services to companies and job seekers.
Italy OJM
Open Up Group Inc. Logo
Provides staffing and outsourcing of engineers for global manufacturing, IT, and construction sectors.
Japan 2154

Talk to a Data Expert

Have a question? We'll get back to you promptly.